Allergan to present anti-infective data at ECCMID

Allergan, a worldwide leader in the development of treatments design to combat infectious diseases, has released new data from its anti-infective portfolio.

The company will be presenting the data in the form of 20 abstracts at the European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam (ECCMID) on April 9-12.

The data Allergan will be presenting at the ECCMID is from studies that further investigated patterns of treatment and the outcome of the clinical study of AVYCAZ (cerftazidime and avibactam) to treat complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) that are hard to treat, which are caused by designated susceptible Gram-negative isolates; clinical outcomes of patients suffering from acute bacterial skin and skin structure infections (ABSSSI) who have been treated with single-dose DALVANCE (dalbavancin) therapy; and in vitro activity and medical results for TEFLARO (ceftaroline fosmail) in patients suffering from complicated skin and soft tissue infections (cSSTI), community-acquired bacterial pneumonia (CAP), coexisting bacteremia and methicillin-resistant Staphylococcus aureus (MRSA).

Vice President of Clinical Development, Anti-Infectives, at Allegran, David Melnick, M.D., will also be presenting data from six Phase 3 trials for TEFLARO, which is designed to treat patients with cSSTI or CAP and concurrent bacteremia.